Protein Summary
Essential for the first step in the synthesis of diphthamide, a post-translational modification of histidine which occurs in elongation factor 2 (EEF2) and which can be ADP-ribosylated by diphtheria toxin and by Pseudomonas exotoxin A (Eta). Down-regulation increases extracellular release of proteoglycans, indicating a possible role in the secretion process. Stimulates binding of GNEFR to SEC5. This gene encodes a CSL zinc finger-containing protein that is required for dipthamide biosynthesis. The encoded protein is necessary for the initial step in the modification of a histidine residue in elongation factor-2 to diphthamide. This modified residue is a target for ADP ribosylation by the bacterial toxins diphtheria toxin and Pseudomonas exotoxin A. Alternative splicing results in multiple transcript variants that encode the same isoform. [provided by RefSeq, Feb 2009]
- ENST00000383775
- ENSP00000373285
- ENSG00000154813
- ENST00000488423
- ENSP00000419599
- DESR1
- ZCSL2
- DESR1
- DPH3A
- KTI11
- ZCSL2
- DELGIP
- DELGIP1
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
histone modification site profile | 0.89 | ||
transcription factor binding site profile | 0.84 | ||
transcription factor perturbation | 0.84 | ||
kinase perturbation | 0.76 | ||
virus perturbation | 0.72 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 26.32 (req: < 5)
Gene RIFs: 3 (req: <= 3)
Antibodies: 36 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 26.32 (req: >= 5)
Gene RIFs: 3 (req: > 3)
Antibodies: 36 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 5
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0